Company Description
Aspen Neuroscience is a leading, clinical-stage regenerative medicine biotechnology company focused on developing autologous induced-pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases with high unmet medical need.
Our lead product candidate, sasineprocel, is an investigational single-dose, autologous iPSC-based cell therapy being evaluated for the treatment of Parkinson’s disease (PD).
We believe sasineprocel has the potential to be disease-modifying by primarily replacing a patient’s lost dopaminergic (DA) neurons with dopaminergic neuron precursor cells (DANPCs).
In an ongoing Phase 1/2a ASPIRO clinical trial of sasineprocel in mid-stage to moderately advanced sporadic PD, patients have experienced, what we believe to be, sustained and clinically meaningful improvements in motor, quality of life, and non-motor symptoms as measured by comparison to clinically meaningful change benchmarks.
Based on these findings, we believe sasineprocel has the potential to improve upon the current standard of care in PD and address the significant unmet need in PD for a disease-modifying therapy that may slow or halt the progression of this devastating disease.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 120 |
| CEO | Damien McDevitt, Ph.D. |
Contact Details
Address: 10835 Road to the Cure, Suite 100 San Diego, CA 92121 United States | |
| Phone | (858) 263-1222 |
| Website | aspenneuroscience.com |
Stock Details
| Ticker Symbol | ASPE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 2124080 |
| Employer ID | 83-1312969 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Damien McDevitt, Ph.D. | President, Chief Executive Officer and Director |
| Faheem Hasnain | Executive Chairman |
| Dalen Meeter | Chief Financial Officer |
| Lisa Johnson-Pratt, M.D. | Sasineprocel Development Lead and Chief Commercial Officer |
| Kim Raineri | Chief Technology Officer |
| Jeffrey Boerneke | General Counsel and Secretary |
| Thomas Daniel, M.D. | Director |
| Douglas Fisher, M.D. | Director |
| Cindy Perettie | Director |
| Caryn Peterson | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 9, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 10, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| May 12, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Mar 30, 2026 | DRS | [Cover] Draft Registration Statement |